Ciclesonide
Alvesco, Omnaris (ciclesonide) is a small molecule pharmaceutical. Ciclesonide was first approved as Omnaris on 2006-10-20. It is used to treat allergic rhinitis perennial and allergic rhinitis seasonal in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Alvesco, Omnaris (discontinued: Zetonna)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ciclesonide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALVESCO | Covis Pharma | N-021658 RX | 2008-01-10 | 2 products, RLD, RS |
| OMNARIS | Covis Pharma | N-022004 RX | 2006-10-20 | 1 products, RLD, RS |
Show 1 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis seasonal | EFO_0003956 | D006255 | J30 |
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Ciclesonide, Alvesco, Covis | |||
| 8371292 | 2028-02-01 | U-1355, U-1356, U-1357 | |
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD13: Ciclesonide
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BA: Glucocorticoid inhalants for obstructive airway disease
— R03BA08: Ciclesonide
HCPCS
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 9 | 25 | 9 | 6 | 49 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 2 | 1 | 24 | 6 | 1 | 34 |
| Allergic rhinitis | D065631 | — | J30.9 | 2 | 1 | 24 | 6 | — | 33 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 14 | 2 | — | 16 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | 1 | 1 | 1 | 3 |
| Respiratory hypersensitivity | D012130 | — | — | — | — | 1 | 2 | — | 3 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | 1 | — | 1 |
| Immune system diseases | D007154 | — | D89.9 | — | — | — | 1 | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | — | 1 | — | 1 |
| Bronchial diseases | D001982 | — | — | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | 15 | — | 1 | 17 |
| Covid-19 | D000086382 | — | — | — | 5 | 4 | — | — | 6 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 2 | 1 | — | — | 2 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | — | 1 |
| Respiratory tract diseases | D012140 | — | — | — | — | 1 | — | — | 1 |
| Polyps | D011127 | EFO_0000662 | — | — | — | 1 | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 1 | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | 1 | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 1 | 1 | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Bronchopulmonary dysplasia | D001997 | — | P27.8 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ciclesonide |
| INN | ciclesonide |
| Description | Ciclesonide is an organic molecular entity. |
| Classification | Small molecule |
| Drug class | topical steroids (acetal derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C |
Identifiers
| PDB | — |
| CAS-ID | 126544-47-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2040682 |
| ChEBI ID | — |
| PubChem CID | 6918155 |
| DrugBank | DB01410 |
| UNII ID | S59502J185 (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Ciclesonide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,961 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,713 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use